Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2026-01-04 @ 3:48 PM
Study NCT ID:
NCT02296203
Status:
UNKNOWN
Last Update Posted:
2018-02-15
First Post:
2014-10-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
Sponsor:
Gruppo Oncologico del Nord-Ovest
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10
Start Date Type:
None
Primary Completion Date:
2017-06-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-06-15
Completion Date Type:
ESTIMATED
First Submit Date:
2014-10-15
First Submit QC Date:
None
Study First Post Date:
2014-11-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-02-14
Last Update Post Date:
2018-02-15
Last Update Post Date Type:
ACTUAL